a and b Illustration of the distribution of prescribed doses at the index date in Barnes et al. [78] and two-way matched analyses of extra-fine hydrofluoroalkane beclomethasone dipropionate (EF HFA-BDP) versus chlorofluorocarbon beclomethasone dipropionate (CFC-BDP). (Reprinted from J Clin Exp Allergy, 14 July 2011, Barnes N, Price D, Colice G, et al.: Asthma control with extrafine-particle hydrofluoroalkane–beclometasone vs. large-particle chlorofluorocarbon–beclometasone: a real-world observational study, doi: 10.1111/j.1365-2222.2011.03820.x. [Epub ahead of print], copyright 2011, with permission from John Wiley and Sons.) c and d Illustration of the distribution in Price et al. [77] two-way matched analysis of EF HFA-BDP versus fluticasone propionate (FP). Prescribed doses were significantly different between treatment cohorts in both the initiation and step-up populations for both the EF HFA-BDP versus CFC-BDP and the EF HFA-BDP versus FP matched analyses (P < 0.001). (Reprinted from J Allergy Clin Immunol vol. 126, Price D, Martin RJ, Barnes N, et al.: Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study, pages 511–518 e511-510, copyright 2010, with permission from Elsevier.) Prescribed doses were significantly different between treatment cohorts in both the initiation and step-up populations for both the EF HFA-BDP versus CFC-BDP and the EF HFA-BDP versus FP matched analyses (P < 0.001)